Literature DB >> 21211840

Retinopathy of prematurity in infants weighing less than 500 grams at birth enrolled in the early treatment for retinopathy of prematurity study.

David T Wheeler1, Velma Dobson, Michael F Chiang, Don L Bremer, Ira H Gewolb, Dale L Phelps, Robert J Hardy, William V Good, Rae Fellows, Betty P Tung, Earl A Palmer.   

Abstract

PURPOSE: To describe patient characteristics, classification, and onset of prethreshold retinopathy of prematurity (ROP), and ocular findings at 6 months corrected age in infants with birth weights <500 g who were enrolled in the Early Treatment for Retinopathy of Prematurity (ETROP) Study.
DESIGN: Multicenter randomized clinical trial. PARTICIPANTS: Sixty-three infants with birth weights <500 g who developed ROP and were enrolled in the ETROP Study.
METHODS: Infants <1251 g at birth were logged at 26 study centers from October 1, 2000, to September 30, 2002, and underwent examinations for ROP. Infants who developed ROP and whose parents/legal guardians consented were enrolled in the ETROP Study. Infants who developed high-risk prethreshold ROP were randomized; 1 eye was treated early with peripheral retinal ablation and the other eye was managed conventionally, or, in asymmetric cases, the high-risk eye was randomized to early peripheral retinal ablation or conventional management. All eyes reaching prethreshold ROP were examined when infants reached 6 months corrected age. MAIN OUTCOME MEASURES: Retinopathy of prematurity incidence, characteristics, and ocular findings among participants.
RESULTS: Thirty-four infants reached prethreshold or worse severity in 1 or both eyes. Retinopathy of prematurity was located in zone I in 43.3% of all prethreshold eyes, and plus disease was present in 46.7%. Median postmenstrual age for diagnosis of all prethreshold ROP was 36.1 weeks, but earlier (35.1 weeks) for eyes that developed high-risk prethreshold ROP. In the 27 surviving infants with prethreshold ROP, ophthalmic examination at 6 months corrected age showed a normal posterior pole in 22 (81.5%), a favorable structural outcome with posterior pole abnormalities in 4 (14.8%), and an unfavorable structural outcome (stage 4B) in 1 (3.7%). One infant developed amblyopia, 4 infants developed nystagmus, 4 infants developed strabismus, and 8 infants developed myopia >-5.00 diopters.
CONCLUSIONS: This is the first report on characteristics of prethreshold ROP in infants with birth weights <500 g. These infants are at high risk for developing prethreshold ROP, although many initially achieve a favorable structural outcome. They are at risk of developing strabismus, nystagmus, high myopia, and abnormal retinal structure and should therefore receive continued long-term follow-up. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21211840      PMCID: PMC4381929          DOI: 10.1016/j.ophtha.2010.09.031

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  19 in total

1.  Screening examination of premature infants for retinopathy of prematurity.

Authors: 
Journal:  Pediatrics       Date:  2006-02       Impact factor: 7.124

2.  Genomics and proteomics of retinopathy of prematurity: DNA-based prevention and treatment.

Authors:  W V Good; R L Gendron
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

3.  Multicenter trial of cryotherapy for retinopathy of prematurity. Preliminary results. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1988-04

4.  An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1984-08

5.  15-year outcomes following threshold retinopathy of prematurity: final results from the multicenter trial of cryotherapy for retinopathy of prematurity.

Authors:  Earl A Palmer; Robert J Hardy; Velma Dobson; Dale L Phelps; Graham E Quinn; C Gail Summers; Carol P Krom; Betty Tung
Journal:  Arch Ophthalmol       Date:  2005-03

6.  Multicenter Trial of Cryotherapy for Retinopathy of Prematurity: ophthalmological outcomes at 10 years.

Authors: 
Journal:  Arch Ophthalmol       Date:  2001-08

7.  Risk analysis of prethreshold retinopathy of prematurity.

Authors:  Robert J Hardy; Earl A Palmer; Velma Dobson; C Gail Summers; Dale L Phelps; Graham E Quinn; William V Good; Betty Tung
Journal:  Arch Ophthalmol       Date:  2003-12

8.  Threshold retinopathy at threshold of viability: the EpiBel study.

Authors:  K Allegaert; K de Coen; H Devlieger
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

9.  The incidence of ophthalmologic interventions in children with birth weights less than 1251 grams. Results through 5 1/2 years. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors:  M X Repka; C G Summers; E A Palmer; V Dobson; B Tung; B Davis
Journal:  Ophthalmology       Date:  1998-09       Impact factor: 12.079

10.  Prevalence of myopia between 3 months and 5 1/2 years in preterm infants with and without retinopathy of prematurity. Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors:  G E Quinn; V Dobson; J Kivlin; L M Kaufman; M X Repka; J D Reynolds; R A Gordon; R J Hardy; B Tung; R A Stone
Journal:  Ophthalmology       Date:  1998-07       Impact factor: 12.079

View more
  5 in total

1.  Secondary 12-Month Ocular Outcomes of a Phase 1 Dosing Study of Bevacizumab for Retinopathy of Prematurity.

Authors:  Eric R Crouch; Raymond T Kraker; David K Wallace; Jonathan M Holmes; Michael X Repka; Janine E Collinge; Don L Bremer; Michael E Gray; Heather A Smith; Paul G Steinkuller
Journal:  JAMA Ophthalmol       Date:  2020-01-01       Impact factor: 7.389

Review 2.  Advances in understanding and management of retinopathy of prematurity.

Authors:  Mary Elizabeth Hartnett
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

3.  Identification of candidate genes and pathways in retinopathy of prematurity by whole exome sequencing of preterm infants enriched in phenotypic extremes.

Authors:  Sang Jin Kim; Kemal Sonmez; Ryan Swan; J Peter Campbell; Susan Ostmo; R V Paul Chan; Aaron Nagiel; Kimberly A Drenser; Audina M Berrocal; Jason D Horowitz; Xiaohui Li; Yii-Der Ida Chen; Kent D Taylor; Charles Simmons; Jerome I Rotter; Michael F Chiang
Journal:  Sci Rep       Date:  2021-03-02       Impact factor: 4.996

4.  Effect of foveal morphology on visual acuity in 4-6-year-old children with retinopathy of prematurity: a J-CREST study.

Authors:  Tomo Nishi; Tetsuo Ueda; Yuutaro Mizusawa; Kayo Shinomiya; Yoshinori Mitamura; Naoki Kimura; Fumi Gomi; Akiko Miki; Makoto Nakamura; Takamasa Kinoshita; Shumpei Obata; Masahito Ohji; Takuya Tsuji; Shigeo Yoshida; Nahoko Ogata
Journal:  Sci Rep       Date:  2022-09-30       Impact factor: 4.996

5.  Fatty acid binding protein 4 deficiency protects against oxygen-induced retinopathy in mice.

Authors:  Magali Saint-Geniez; Elisa Ghelfi; Xiaoliang Liang; Chenwei Yu; Carrie Spencer; Stephanie Abend; Gokhan Hotamisligil; Sule Cataltepe
Journal:  PLoS One       Date:  2014-05-06       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.